In the latest session, Fortress Biotech Inc (NASDAQ: FBIO) closed at $2.00 down -7.83% from its previous closing price of $2.17. In other words, the price has decreased by -$0.1700 from its previous closing price. On the day, 311844 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Fortress Biotech Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.89 and its Current Ratio is at 1.00. In the meantime, Its Debt-to-Equity ratio is 4.44 whereas as Long-Term Debt/Eq ratio is at 3.88.
On August 04, 2022, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $6.
On October 02, 2020, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $9.The Benchmark Company initiated its Buy rating on October 02, 2020, with a $9 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’24 when ROSENWALD LINDSAY A MD bought 50,000 shares for $2.38 per share. The transaction valued at 118,770 led to the insider holds 2,863,905 shares of the business.
ROSENWALD LINDSAY A MD bought 1,567,515 shares of FBIO for $2,664,776 on Nov 14 ’23. The President, CEO & Chairman now owns 2,597,440 shares after completing the transaction at $1.70 per share. On Nov 14 ’23, another insider, WEISS MICHAEL S, who serves as the insider of the company, bought 147,058 shares for $1.70 each. As a result, the insider paid 249,999 and bolstered with 1,130,520 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FBIO now has a Market Capitalization of 39.69M and an Enterprise Value of 37.54M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.45 while its Price-to-Book (P/B) ratio in mrq is 0.07. Its current Enterprise Value per Revenue stands at 0.46 whereas that against EBITDA is -0.24.
Stock Price History:
Over the past 52 weeks, FBIO has reached a high of $12.75, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is 1.9478, while the 200-Day Moving Average is calculated to be 4.2262.
Shares Statistics:
For the past three months, FBIO has traded an average of 492.39K shares per day and 347.66k over the past ten days. A total of 18.38M shares are outstanding, with a floating share count of 13.35M. Insiders hold about 27.33% of the company’s shares, while institutions hold 25.49% stake in the company. Shares short for FBIO as of Mar 15, 2024 were 1.73M with a Short Ratio of 3.52, compared to 1.64M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.42% and a Short% of Float of 10.75%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.97 for the current quarter, with a high estimate of -$1.49 and a low estimate of -$2.61, while EPS last year was -$4.46. The consensus estimate for the next quarter is -$1.41, with high estimates of -$1.28 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$6.13 and -$9.36 for the fiscal current year, implying an average EPS of -$7.38. EPS for the following year is -$2.9, with 3 analysts recommending between -$0.4 and -$4.85.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $14.89M this quarter.It ranges from a high estimate of $15.69M to a low estimate of $14.46M. As of the current estimate, Fortress Biotech Inc’s year-ago sales were $16.4M, an estimated decrease of -9.20% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $14.75M, an increase of 18.70% over than the figure of -$9.20% in the same quarter last year. There is a high estimate of $14.87M for the next quarter, whereas the lowest estimate is $14.63M.
A total of 3 analysts have provided revenue estimates for FBIO’s current fiscal year. The highest revenue estimate was $80.26M, while the lowest revenue estimate was $53.28M, resulting in an average revenue estimate of $70.88M. In the same quarter a year ago, actual revenue was $75.74M, down -6.40% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $74.81M in the next fiscal year. The high estimate is $98.63M and the low estimate is $61.62M. The average revenue growth estimate for next year is up 5.50% from the average revenue estimate for this year.
